Meditoxin (Botulinux A toxin) 100 units is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox Inc. and officially launched in Korea since 2006.
Throughout the 1980s and 1990s, Clostridium botulinum had been intensively researched by a group of scientists in Korea. In 2000, the scientists established a biotech venture named “Medy-Tox Inc.” which specializes in botulinum and its toxins. Following much research on biological, biochemical, immunological and toxicity aspects, botulinum toxin type A has been developed as a biopharmaceutical product.
In 2004 and 2005, Meditoxin® has been licensed to famous pharmaceutical companies including Ranbaxy which is one of the biggest generics companies in the world and a Korean pharmaceutical company, CJ Corp., which will launch Meditoxin® in the Latin America of more than 50 countries. Furthermore, Q-MED has been the marketing and distributorship partner of Meditoxin® for Europe and Japan since early 2007. All these licensing cases show the credibility of Meditoxin®
MEDITOXIN®, the First Choice of Botulinum Toxin Type A Pharmaceutical has the best value proposition in terms of its price and quality. MEDITOXIN® is a biosame form of Botox® (Allergan, USA).